



DBV Technologies and Mount Sinai Hospital enter into a Research Collaboration Agreement

BAGNEUX, FRANCE, 7 May 2013 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin[®], a new standard in the treatment of allergies, announced today a partnership with the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai (New York) for research related to the mechanism by which epicutaneous immunotherapy (EPIT[®]) using Viaskin[®] leads to immune tolerance to food antigens. Drs. Cecilia Berin and Hugh Sampson will be principal investigators for the collaborative research. Dr. Sampson is also director of the Jaffe Food Allergy Institute, whose mission is to expand and improve basic science and clinical research, comprehensive patient care, and educational efforts in the field of food allergy.

Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said, *“The establishment of a partnership with Mount Sinai will allow for increased knowledge regarding our epicutaneous immunotherapy method. Today, we have put in place landmark partnerships on EPIT[®] that we believe show the scientific and medical value of our approach. The research partnership announced today will help DBV better design mechanistic studies in its clinical trials and better identify patient responders. We are extremely proud to be able to work with Drs. Hugh Sampson and Cecilia Berin on such cutting edge research.”*

The research program will be conducted over an 18-month period. The study objectives are focused on the efficacy of EPIT in food induced gastro-intestinal allergies. A first study will be focused on the EPIT[®] method as a treatment of food-induced anaphylaxis in mice, compared to oral immunotherapy (OIT). A second study will address the mechanism of tolerance induction, particularly the importance of the skin immune milieu and mechanism of regulatory T cells induction in the development of tolerance.

About peanut allergy: a life-threatening risk for millions of people

In the US, about 1.1% of the general population, or over 3 million people, is allergic to peanuts, which results in about 100 to 150 deaths per year. This allergy affects both adults and children, and in the United Kingdom, it has been estimated that peanut allergy affects 1.8% of young children. The prevalence of peanut allergy in other Western countries (e.g., Canada, France and Spain) has been studied by many researchers, and the prevalence ranges from 0.9% to 1.5%. Peanut allergy is generally considered to be persistent; many studies indicate that fewer than 20% of children will outgrow their allergy. Peanut allergy is more severe than other common food allergies, including milk and egg allergies.

About DBV Technologies

DBV Technologies is developing Viaskin[®], an innovative new approach to the treatment of allergies – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people, constituting a major unmet medical need. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood. The Viaskin[®] technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanuts, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure. The product's clinically proven safety profile enables the application of effective desensitization techniques in the most severe forms of the allergy.

DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin[®] Peanut and Viaskin[®] Milk. The clinical development program for Viaskin[®] Peanut has received Fast Track designation from the US Food and Drug Administration and is currently being studied in Phase II program. The company will subsequently develop a Viaskin[®] patch for young children with house dust mite allergy – a true public health issue because this pathology is a primary risk factor for childhood asthma.



DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

DBV Contacts

DBV Technologies

David Schilansky
Chief Financial Officer
Tél. : +33(0)1 55 42 78 75
david.schilansky@dbv-technologies.com

US & UK investors

The Trout Group
Investor Relations
Alan S. Roemer
Tél. : +1 (646) 378-2945
aroemer@troutgroup.com

French investors

NewCap.
Financial Communication and investor relations
Emmanuel Huynh / Valentine Brouchet
Tél. : +33(0)1 44 71 94 94
dbv@newcap.fr

US press & media

Ronald Trahan, APR
Press relations
Ronald Trahan
Tél. : +1 508 359 4005
rctrahan@ronaldtrahan.com